Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus

To assess the utility of existing metabolomics scores to classify liver disease in patients with type 2 diabetes mellitus (T2DM).

[1]  K. Cusi,et al.  Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  P. Aschner.  F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .

[3]  Shelly C. Lu,et al.  Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. , 2017, Gastroenterology.

[4]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[5]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. , 2016, Endocrinology and metabolism clinics of North America.

[6]  J. Tomlinson,et al.  Non-alcoholic fatty liver disease and diabetes , 2016, Metabolism: clinical and experimental.

[7]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[8]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[9]  Ibon Martínez-Arranz,et al.  Enhancing metabolomics research through data mining. , 2015, Journal of proteomics.

[10]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  B. Neuschwander‐Tetri,et al.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD , 2015, Diabetes Care.

[12]  K. Cusi,et al.  Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease , 2014, Current Hepatology Reports.

[13]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  Jen-Jung Pan,et al.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD , 2013, Biomarker Research.

[15]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[16]  Shelly C. Lu,et al.  Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. , 2012, Journal of proteome research.

[17]  Qiwen Ben,et al.  Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: A systematic review and meta‐analysis of cohort studies , 2012, International journal of cancer.

[18]  M. Bulsara,et al.  Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[19]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[20]  T. Saibara,et al.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.

[21]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[23]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[24]  V. de Lédinghen,et al.  Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease , 2006, BMC gastroenterology.

[25]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[26]  R. DeFronzo,et al.  A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.